Revista espanola de enfermedades digestivas · 2026
Results of a hepatitis C microelimination project in an addiction treatment center.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodríguez-Seguel Elisa, Ruiz Pérez Ricardo, Pérez-Godoy Díaz Enrique, Lozano Domínguez María Del Carmen, Giráldez Gallego Álvaro, Desongles Corrales Trinidad, Ferrer Ríos María Teresa, Sousa Martín José Manuel, Pascasio Acevedo Juan Manuel
Аннотация
BACKGROUND: patients on opioid substitution therapy constitute a group with a high burden of hepatitis C and candidates for interventions aimed at microelimination.
AIMS: to analyze the baseline prevalence of both previous contact and/or active infection, measure the response to current treatment provided through a simplified circuit and estimate the impact of this intervention on the reduction of the proportion of the viremic population.
METHODS: people affiliated to an addiction treatment center underwent an in situ diagnostic sequence using saliva serological screening and viremia quantification with a dry blood spot test. Viremic patients were linked to care and treatment, which was administered in the first single appointment with pan-genotypic direct-acting antivirals. The McNemar test was used to compare the proportion of active infection before and after intervention.
RESULTS: with a participation rate of 99.2 %, the seroprevalence for hepatitis C was 44.6 % (115/258) while active infection was present in 20.9 % of seropositive individuals (24/115). The response rate to treatment was 54.2 % by intention-to-treat and 61.9 % by per-protocol analysis. Successful treatment of 13 patients resulted in an estimated global reduction of the active infection rate from 9.3 % to 4.3 % (p = 0.0002), for a theorical scenario with no reinfections. By adjusting for the known reinfection rates, the prevalence of active infection also decreased to 4.2 % for individuals without assumed recent drug use (p = 0.0074), but no changes were found for estimates in patients with a supposed recent drug use (p = 0.2632).
CONCLUSIONS: focused efforts targeted to this high-risk group, including both screening and treatment initiatives, can potentially reduce the prevalence of active hepatitis C infections.
AIMS: to analyze the baseline prevalence of both previous contact and/or active infection, measure the response to current treatment provided through a simplified circuit and estimate the impact of this intervention on the reduction of the proportion of the viremic population.
METHODS: people affiliated to an addiction treatment center underwent an in situ diagnostic sequence using saliva serological screening and viremia quantification with a dry blood spot test. Viremic patients were linked to care and treatment, which was administered in the first single appointment with pan-genotypic direct-acting antivirals. The McNemar test was used to compare the proportion of active infection before and after intervention.
RESULTS: with a participation rate of 99.2 %, the seroprevalence for hepatitis C was 44.6 % (115/258) while active infection was present in 20.9 % of seropositive individuals (24/115). The response rate to treatment was 54.2 % by intention-to-treat and 61.9 % by per-protocol analysis. Successful treatment of 13 patients resulted in an estimated global reduction of the active infection rate from 9.3 % to 4.3 % (p = 0.0002), for a theorical scenario with no reinfections. By adjusting for the known reinfection rates, the prevalence of active infection also decreased to 4.2 % for individuals without assumed recent drug use (p = 0.0074), but no changes were found for estimates in patients with a supposed recent drug use (p = 0.2632).
CONCLUSIONS: focused efforts targeted to this high-risk group, including both screening and treatment initiatives, can potentially reduce the prevalence of active hepatitis C infections.